ASSOCIATION BETWEEN APOLIPOPROTEIN B AND IN-HOSPITAL CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROME
Main Article Content
Abstract
Background: the prognostic value of Apolipoprotein B (Apo B) for in-hospital mortality in elderly patients with acute coronary syndrome is a topic of growing clinical interest. However, relevant data in the Vietnamese population remain limited. Objective: to investigate the association between Apo B levels and in-hospital clinical outcomes in elderly patients with acute coronary syndrome. Subjects and Methods: this was a descriptive cross-sectional study. The study population included patients aged ≥ 60 years who were admitted with a diagnosis of acute coronary syndrome and underwent coronary angiography confirming significant coronary artery disease, from August 2024 to June 2025, at the Department of Emergency and Interventional Cardiology, Thong Nhat Hospital. Results: a total of 337 patients were enrolled. The mean age was 70.1 ± 7.3 years, with males accounting for 65.9%. The median Apo B level was 96.2 mg/dL (IQR: 86.2 - 116.8). Multivariate analysis revealed that patients with elevated Apo B levels had a 3.2-fold higher risk of in-hospital mortality compared to those with lower Apo B levels (OR = 3.2; 95% CI: 1.1 - 11.4; p = 0.04). In addition, age ≥ 80 years and Killip class III - IV were also identified as independent predictors of mortality. Conclusions: Apo B is an independent prognostic factor associated with increased in-hospital mortality in elderly patients with acute coronary syndrome.
Article Details
Keywords
Apolipoprotein B, acute coronary syndrome, elderly patients
References
2. Tuấn VA, Giang NTH, Dung ĐTN. Nghiên cứu sự biến đổi nồng độ LP-PLA2, APO AI, APO B, tỷ số APO B/APO AI huyết thanh trong bệnh động mạch vành. Tạp chí Nghiên cứu Y học. 2021;140(4):194-202.
3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146-e603.
4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal. 2020;41(1):111-188.
5. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS medicine. 2020;17(3):e1003062.
6. Shechter M, Bairey Merz CN, Paul-Labrador MJ, Shah PK, Kaul S. Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease. Cardiology. 2000;92(3):151-155.
7. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The lancet. 2004;364(9438):937-952.
8. Zhang J, Song X, Li Z, et al. Association of apolipoprotein levels with all-cause and cardiovascular mortality. European Journal of Preventive Cardiology. 2024;31(9):1183-1194.